Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) ...
What are the projected timelines and potential revenue milestones from development through commercialization, and how could they affect long‑term valuation?
What is the competitive landscape for ACTH receptor antagonists and how does atumelnant's first‑in‑class status affect CRNX's market positioning?
How might the FDA orphan drug designation for atumelnant influence CRNX's short‑term stock price and trading volume?
3 days ago